Is there evidence for vasculitis in systemic sclerosis

Current Rheumatology Reports

Volumn 14, Issue 6, 2012, Pages 516-525

  Saketkoo, Lesley Ann ^a   Distler, Oliver ^b  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

ANCA; Angiogenesis; Endothelial cells; Scleroderma; Systemic sclerosis; Vasculitis; Vasculogenesis; Vasculopathy

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; NEUTROPHIL CYTOPLASMIC ANTIBODY; TRANSCRIPTION FACTOR FRA 2;

ANCA ASSOCIATED VASCULITIS; ANGIOGENESIS; APOPTOSIS; AUTOIMMUNITY; CLINICAL FEATURE; DRUG MEGADOSE; ENDOTHELIUM INJURY; FIBROSIS; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; MICROANGIOPATHY; NONHUMAN; PATHOGENESIS; REVIEW; RISK FACTOR; STEM CELL TRANSPLANTATION; SYSTEMIC SCLEROSIS; VASCULAR DISEASE; VASCULITIS;

HUMANS; INFLAMMATION; SCLERODERMA, SYSTEMIC; VASCULAR DISEASES; VASCULITIS;

EID: 84869159787     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-012-0296-9     Document Type: Review

References (81)

1. Denton CP, Korn JH. Digital ulceration and critical digital ischaemia in scleroderma. Scleroderma Care Res. 2003; 1: 12-6.
2. Nihtyanova SI, Brough G, Black CM, Denton CP. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2008; 67: 120-3.
3. Avouac J, Guerini H, Wipff J, Assous N, Chevrot A, Kahan A, et al. Radiological hand involvement in systemic sclerosis. Ann Rheum Dis. 2006; 65(8): 1088-92. (Pubitemid 44133273)
4. La Montagna G, Sodano A, Capurro V, Malesci D, Valentini G. The arthropathy of systemic sclerosis: a 12 month prospective clinical and imaging study. Skeletal Radiol. 2005; 34: 35-41. (Pubitemid 40089752)
5. Ranque B, Bé rezné A, Le-Guern V, Pagnoux C, Allanore Y, Launay D, et al. Myopathies related to systemic sclerosis: a case-control study of associated clinical and immunological features. Scand J Rheumatol. 2010; 39: 498-505.
6. Marie I, Levesque H, Ducrotté P, et al. Gastric involvement in systemic sclerosis: a prospective study. Am J Gastroenterol. 2001; 96: 77-83. (Pubitemid 32104811)
7. Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis. 2007; 66: 754-63. (Pubitemid 46846694)
8. Allanore Y, Meune C, Vonk MC, Airo P, Hachulla E, Caramaschi P, et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis. 2010; 69: 218-21.
9. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007; 66: 940-4. (Pubitemid 46999798)
10. Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010; 69(10): 1809-15.
11. Riemekasten G, Philippe A, Nä ther M, Slowinski T, Mü ller DN, Heidecke H, et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis. 2011; 70: 530-6. Landmark article demonstrating autoimmunity as a mediator of vascular pathology in SSc and correlation to vascular manifestations and mortality.
12. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006; 354: 2667-76.
13. Barnes J, Mayes MD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol. 2012; 24(2): 165-70.
14. Jimenez SA, Diaz A, Khalili K. Retroviruses and the pathogenesis of systemic sclerosis. Int Rev Immunol. 1995; 12(2-4): 159-75.
15. Kahaleh B. Vascular disease in scleroderma: mechanisms of vascular injury. Rheum Dis Clin N Am. 2008; 34(1): 57-71. vi. (Pubitemid 351329463)
16. Neidhart M, Kuchen S, Distler O, Brü hlmann P, Michel BA, Gay RE, et al. Increased serum levels of antibodies against human cytomegalovirus and prevalence of autoantibodies in systemic sclerosis. Arthritis Rheum. 1999; 42: 389-92. (Pubitemid 29072859)
17. Broen JC, Coenen MJ, Radstake TR. Genetics of systemic sclerosis: an update. Curr Rheumatol Rep. 2012; 14(1): 11-21.
18. Manetti M, Allanore Y, Revillod L, Fatini C, Guiducci S, Cuomo G, et al. A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis. Arthritis Rheum. Jan; 63(1): 247-56.
19. Romano E, Manetti M, Guiducci S, Ceccarelli C, Allanore Y, Matucci-Cerinic M. The genetics of systemic sclerosis: an update. Clin Exp Rheumatol. 2011; 29(2 Suppl 65): S75-86.
20. Sharif R, Mayes MD, Tan FK, Gorlova OY, Hummers LK, Shah AA, et al. IRF5 polymorphism predicts prognosis in patients with systemic sclerosis. Ann Rheum Dis. 2012; 71(7): 1197-202.
21. Basu N,Watts R, Bajema I, Baslund B, Bley T, BoersM, et al. EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis. 2010; 69(10): 1744.
22. De Angelis R, Grassi W, Cutulo M. A growing need for capillaroscopy in rheumatology. Arthritis Rheum. 2009; 61(3): 405-10.
23. Del Papa N, Quirici N, Soligo D, Scavullo C, Cortiana M, Borsotti C, et al. Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum. 2006; 54: 2605-15. (Pubitemid 44205023)
24. Distler O, Distler JH, Scheid A, Acker T, Hirth A, Rethage J, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res. 2004; 95: 109-16. (Pubitemid 38931842)
25. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 2008; 58(12): 3902-12.
26. Lambova SN, Muller-Ladner U. Capillaroscopic pattern in systemic sclerosis-an association with dynamics of process of angio- and vasculogensis. Microvasc Res. 2010; 80(3): 534-9.
27. Murray AK, Moore TL, King TA, Herrick AL. Abnormal microvascular response is localized to the digits in patients with systemic sclerosis. Arthritis Rheum. 2006; 54(6): 1952-60. (Pubitemid 43877945)
28. Murray AK, Vail A, Moore TL, Manning JB, Taylor CJ, Herrick AL. The influence of measurement location on reliability of quantitative nailfold videocapillaroscopy in patients with SSc. Rheumatology (Oxford). 2012; 51(7): 1323-30. Demonstrates importance of high power magnification and original location in assessment of capillaroscopic changes.
29. Von Bierbrauer A, Barth P, Willert J, Baerwald C, Mennel HD, Schmidt JA. Electron microscopy and capillaroscopically guided nailfold biopsy in connective tissue diseases: detection of ultrastructurual changes of the microcirculatory vessels. Br J Rheum. 1998; 37: 1272-8.
30. Youssef P, Brama T, Englert H, Bertouch J. Limited scleroderma is associated with increased prevalence of macrovascular disease. J Rheumatol. 1995; 22(3): 469-72.
31. Stafford L, Englert H, Gover J, Bertouch J. Distribution of macrovascular disease in scleroderma. Ann RheumDis. 1998; 57(8): 476-9. (Pubitemid 28428217)
32. Frerix M, Stegbauer J, Dragun D, Kreuter A, Weiner SM. Ulnar artery occlusion is predictive of digital ulcers in SSc: a duplex sonography study. Rheumatology (Oxford). 2012; 51(4): 735-42. Epub 2011 Dec 20. Demonstrates the need for further investigation of macrovasculopathy in SSc.
33. Fleming JN, Nash RA, McLeod DO, Fiorentino DF, Shulman HM, Connolly MK, et al. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS One. 2008; 3(1): e1452.
34. Antonios TF, Singer DR, Markandu ND, Mortimer PS, MacGregor GA. Rarefaction of skin capillaries in borderline essential hypertension suggests an early structural abnormality. Hypertension. 1999; 34: 655-8. (Pubitemid 29496449)
35. Houben AJ, Beljaars JH, Hofstra L, Kroon AA, De Leeuw PW. Microvascular abnormalities in chronic heart failure: a crosssectional analysis. Microcirculation. 2003; 10: 471-8 [PubMed]. (Pubitemid 39004273)
36. D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (Scleroderma). Am J Med. 1969; 46 (3): 428-39.
37. Cho H, Kozasa T, Bondjers C, Betsholtz C, Kehrl JH. Pericytespecific expression of RGS5: implications for PDGF and EDG receptor signaling during vascular maturation. FASEB J. 2003; 17: 440-2.
38. Overbeek MJ, Vonk MC, Boonstra A, Voskuyl AE, Vonk- Noordgraaf A, Smit EF, et al. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis a distinctive vasculopathy. Eur Respir J. 2009; 34: 371-9. Demonstrates pathologic differences in vasculopathy between idiopathic and pulmonary arterial hypertension associated with SSc. These findings may have implications for response to treatment.
39. Dorfmü ller P, Humbert M, Perros F, Sanchez O, Simonneau G, Mü ller KM, et al. Fibrous remodling of the pulmonary venous system in pulmonary arterial hypertension asscociated with the connective tissue diseases. Hum Pathol. 2007; 38: 893-902.
40. Arad U, Balbir-Gurman A, Doenyas-Barak K, Amit-Vazina M, Caspi D, Elkayam O. Anti-neutrophil antibody associated vasculitis in systemic sclerosis. Semin Arthritis Rheum. 2011; 41 (2): 223-9. Examines a large cohort of SSc patients for association of ANCA reactivity.
41. Merkel PA, Polisson RP, Chang Y, Skates SJ, Niles JL. Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med. 1997; 126(11): 866-73. (Pubitemid 27232627)
42. Ruffatti A, Sinico RA, Radice A, Ossi E, Cozzi F, Tonello M, et al. Autoantibodies to proteinase 3 and myeloperoxidase in systemic sclerosis. J Rheumatol. 2002; 29(5): 918-23. (Pubitemid 34493493)
43. Huong DL, Papo T, Gatfosse M, Frances C, Godeau P, Beaufils H. Antineutrophil cytoplasmic autoantibodies in systemic sclerosis with renal failure. J Rheumatol. 1995; 22(4): 791-2.
44. Derrett-Smith EC, Nihtyanova S, Parker J, Bunn C, Burns A, Little MA, et al. Clinical significance of defined ANCA positivity in systemic sclerosis. [abstract]. Arthritis Rheum. 2010; 62 Suppl 10: 1207.
45. Kamen DL, Wigley FM, Brown AN. Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis in scleroderma-a different kind of renal crisis. J Rheumatol. 2006; 33(9): 1886.
46. Maurer B, Reich N, Jü ngel A, Kriegsmann J, Gay RE, Schett G, et al. Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Ann Rheum Dis. 2012. This study further demonstrates the role of Fra-2 in vascular and fibrotic manifestations of SSc.
47. Maurer B, Busch N, Jü ngel A, Pileckyte M, Gay RE, Michel BA, et al. Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. Circulation. 2009; 120: 2367-76.
48. Sambo P, Baroni SS, Luchetti M, Paroncini P, Dusi S, Orlandini G, et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum. 2001; 44: 2653-64. (Pubitemid 33049343)
49. Servettaz A, Guilpain P, Goulvestre C, Ché reau C, Hercend C, Nicco C, et al. Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis. Ann Rheum Dis. 2007; 66: 1202-9. (Pubitemid 47309738)
50. Sturrock A, Cahill B, Norman K, Huecksteadt TP, Hill K, Sanders K, et al. Transforming growth factor-beta1 induces Nox4 NAD (P)H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2005; 290: L661-73.
51. Svegliati S, Cancello R, Sambo P, Luchetti M, Paroncini P, Orlandini G, et al. Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2: amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem. 2005; 280: 36474-82. (Pubitemid 41633921)
52. Ahmed SS, Tan FK, Arnett FC, Jin L, Geng YJ. Induction of apoptosis and fibrillin-1 expression in human dermal endothelial cells by scleroderma sera containing antiendothelial cell antibodies. Arthritis Rheum. 2006; 54: 2250-62. (Pubitemid 44051083)
53. Del Papa N, Quirici N, Scavullo C, Gianelli U, Corti L, Vitali C, et al. Antiendothelial cell antibodies induce apoptosis of bone marrow endothelial progenitors in systemic sclerosis. J Rheumatol. 2010; 37(10): 2053-63. Demonstrates role of AECAs in defective angiogenesis in SSc.
54. Distler JH, Beyer C, Schett G, Lü scher TF, Gay S, Distler O. Endothelial progenitor cells: novel players in the pathogenesis of rheumatic diseases. Arthritis Rheum. 2009; 60: 3168-79.
55. Distler JH, Allanore Y, Avouac J, Giacomelli R, Guiducci S, Moritz F, et al. EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells. Ann Rheum Dis. 2009; 68: 163-8. Establishes standardization for assessment and handling of EPCs in research.
56. Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Defective vasculogenesis in systemic sclerosis. Lancet. 2004; 364: 603-10. (Pubitemid 39094178)
57. Pignone A, Scaletti C, Matucci-Cerinic M, Vá zquez-Abad D, Meroni PL, Del Papa N, et al. Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol. 1998; 16(5): 527-32. (Pubitemid 28439433)
58. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest. 1996; 98(3): 785-92. (Pubitemid 26349184)
59. Dragun D, Catar R, Kusch A, Heidecke H, Philippe A. Non-HLAantibodies targeting angiotensin type 1 receptor and antibody mediated rejection. Hum Immunol. 2012 Jul 20.
60. Wallukat G, Neichel D, Nissen E, Homuth V, Luft FC. Agonistic autoantibodies directed against the angiotensin II AT1 receptor in patients with preeclampsia. Can J Physiol Pharmacol. 2003; 81 (2): 79-83. (Pubitemid 36398878)
61. Arefiev K, Fiorentino DF, Chung L. Endothelin receptor antagonists for the treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis. Int J Rheumatol. 2011; 2011: 201787.
62. Rubin LJ. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension. Life Sci. 2012 Aug 3.
63. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003; 348: 593-600. (Pubitemid 36204953)
64. Davies CA, Jeziorska M, Freemont AJ, Herrick AL. The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum Pathol. 2006; 37: 190-7. (Pubitemid 43099839)
65. De Groot K, Goldberg C, Bahlmann FH, Woywodt A, Haller H, Fliser D, et al. Vascular endothelial damage and repair in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2007; 56: 3847-53. (Pubitemid 350100717)
66. Kuwana M, Okazaki Y. Quantification of circulating endothelial progenitor cells in systemic sclerosis: a direct comparison of protocols. Ann Rheum Dis. 2012. Demonstrates the importance of assay method in research incorporating EPC assays.
67. Avouac J, Juin F,Wipff J, Couraud PO, Chiocchia G, Kahan A, et al. Circulating endothelial progenitor cells in systemic sclerosis: association with disease severity. Ann Rheum Dis. 2008; 67: 1455-60.
68. Avouac J, Cagnard N, Distler JH, Schoindre Y, Ruiz B, Couraud PO, et al. Insights into the pathogenesis of systemic sclerosis based on the gene expression profile of progenitor-derived endothelial cells. Arthritis Rheum. 2011; 63(11): 3552-62.
69. Avouac J, Meune C, Ruiz B, Couraud PO, Uzan G, Boileau C, et al. Angiogenic biomarkers predict the occurrence of digital ulcers in systemic sclerosis. Ann Rheum Dis. 2012; 71(3): 394-9. Demonstrates the correlation of circulating EPCs and other angiogenic factors with vascular manifestations of SSc. These findings may help to stratify risk in SSc patients.
70. Distler O, Distler JH, Scheid A, Acker T, Hirth A, Rethage J, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res. 2004; 95(1): 109-16. (Pubitemid 38931842)
71. Distler JH, Akhmetshina A, Dees C, Jü ngel A, Stü rzl M, Gay S, et al. Induction of apoptosis in circulating angiogenic cells by microparticles. Arthritis Rheum. 2011; 63(7): 2067-77. Highlights important area of research of vascular pathology in SSc.
72. Manetti M, Guiducci S, Romano E, Ceccarelli C, Bellando- Randone S, Conforti ML, et al. Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res. 2011; 109(3): e14-26. Epub 2011 Jun 2.
73. D'Alessio S, Fibbi G, Cinelli M, Guiducci S, Del Rosso A, Margheri F, et al. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum. 2004; 50(10): 3275-85. (Pubitemid 39372005)
74. Iwamoto N, Vettori S, Maurer B, Brock M, Calcagni M, Gay RE, et al. Downregulation of miR-193b in systemic sclerosis regulates the proliferation vasculopathy by urokinase type plasminogen activator expression. American College of Rheumatology Annual Scientific Meeting 2011 November: Abstract 0605.
75. Postiglione L, Montuori N, Riccio A, Di Spigna G, Salzano S, Rossi G, et al. The plasminogen activator system in fibroblasts from systemic sclerosis. Int J Immunopathol Pharmacol. Jul-Sep; 23(3): 891-900.
76. Margheri F, Manetti M, Serratì S, Nosi D, Pucci M, Matucci-Cerinic M, et al. Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, beta2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. Arthritis Rheum. 2006; 54(12): 3926-38. (Pubitemid 44955896)
77. Margheri F, Serratì S, Lapucci A, Chillà A, Bazzichi L, Bombardieri S, et al. Modulation of the angiogenic phenotype of normal and systemic sclerosis endothelial cells by gain-loss of function of pentraxin 3 and matrix metalloproteinase 12. Arthritis Rheum. 2010; 62(8): 2488-98. Highlights the role of MMP-12 and uPAR in vascular pathogenesis of SSc.
78. Helmbold P, Fiedler E, Fischer M, Marsch WC. Hyperplasia of dermal microvascular pericytes in scleroderma. J Cutan Pathol. 2004; 31: 431-40. (Pubitemid 38845134)
79. Dees C, Akhmetshina A, Pawel Z, Reich N, Palumbo K, Horn A, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med. 2011; 208(5): 961-72.
80. Distler JH, Akhmetshina A, Schett G, Distler O. Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis. Rheumatology (Oxford). 2009; 48: 98-103.
81. Distler O, Pap T, Kowal-Bielecka O, Meyringer R, Guiducci S, Landthaler M, et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum. 2001; 44: 2665-78. (Pubitemid 33049344)